7 -20 November 2020
These are links to recent news stories about multiple sclerosis that may be of interest to people affected by MS in the UK. The link beneath each item will take you to the original story.
Please note that the MS Trust did not write the original items and does not endorse their content nor any claims made in them.
To keep up to date on all the latest news, views and research on multiple sclerosis, sign up for Open Door, our free newsletter, or regular email alerts.
New study for advanced MS
A UK study will explore whether Mavenclad can slow progression of upper limb disability in people with advanced MS. People with mobility problems are usually excluded from trials, which tend to focus on walking ability. The ChariotMS study will recruit 200 people at centres around the UK. People who think they might be eligible should talk to their neurologist or MS nurse about a possible referral.
MS Trust link: Mavenclad (cladribine)
Campaign for fair benefits during the pandemic
The Disability Benefits Consortium - an umbrella group of more than 100 charities - is calling for equality for people who have not yet been moved to Universal Credit. People who get Universal Credit, which combines several previously separate benefits, have been receiving an extra £20 per week during the pandemic. People who are still receiving the individual benefits haven't had this support.
MS Trust link: Benefits
Stem cells compared to Lemtrada
More people treated with stem cells (AHSCT) showed no signs of disease activity (NEDA) than a people treated with Lemtrada, according to a Swedish study. Three years after treatment, almost nine in ten of the AHSCT group showed no new relapses, no new lesions and no progression. In the Lemtrada group the rate was almost four in ten. More comparison studies are currently under way.
Source: MS News Today
DMD use and finances
Delaying starting a disease modifying drug (DMD) was associated with a more rapid drop in earnings or sooner reliance on benefits compared to people who started treatment within two years of onset of MS, according to a Swedish study.
Source: Managed Health Executive
MS Trust link: Disease modifying drugs for relapsing MS
David Martin appointed Chair of the Neurological Alliance
18 Nov 2020 - 00:00
The MS Trust is delighted to announce that CEO David Martin, has been voted in as Chair of the Neurological Alliance.
My MS and my mental health
16 Nov 2020 - 00:00
In his latest blog, Ian Daly speaks candidly about his own experience with depression and urges others to seek help if needed.
Thank you to the National Lottery Community Fund
10 Nov 2020 - 00:00
The MS Trust has been awarded £50,000 from the Coronavirus Community Support Fund, distributed by The National Lottery Community Fund for our ‘Supporting the MS community during Covid-19’ project.